SG11201608608PA - Rapid relief of motor fluctuations in parkinson's disease - Google Patents

Rapid relief of motor fluctuations in parkinson's disease

Info

Publication number
SG11201608608PA
SG11201608608PA SG11201608608PA SG11201608608PA SG11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA SG 11201608608P A SG11201608608P A SG 11201608608PA
Authority
SG
Singapore
Prior art keywords
parkinson
disease
rapid relief
motor fluctuations
fluctuations
Prior art date
Application number
SG11201608608PA
Other languages
English (en)
Inventor
Richard P Batycky
Martin Freed
Michael M Lipp
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of SG11201608608PA publication Critical patent/SG11201608608PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11201608608PA 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease SG11201608608PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Publications (1)

Publication Number Publication Date
SG11201608608PA true SG11201608608PA (en) 2016-11-29

Family

ID=54332876

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608608PA SG11201608608PA (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Country Status (14)

Country Link
US (2) US20170296498A1 (ja)
EP (2) EP3831375A1 (ja)
JP (1) JP2017513866A (ja)
KR (2) KR20170008754A (ja)
CN (2) CN113209055A (ja)
AU (2) AU2014391721B2 (ja)
BR (1) BR112016024502A8 (ja)
CA (1) CA2946165C (ja)
IL (2) IL309959A (ja)
MX (1) MX2016013741A (ja)
RU (1) RU2698330C2 (ja)
SG (1) SG11201608608PA (ja)
WO (1) WO2015163840A1 (ja)
ZA (1) ZA201607833B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
BR112020013749A2 (pt) * 2018-01-05 2020-12-01 Impel Neuropharma, Inc. dispensação intranasal de pó de levodopa por dispositivo olfativo de precisão
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
ES2389156T3 (es) * 2002-03-20 2012-10-23 Civitas Therapeutics, Inc. Administración pulmonar de levodopa
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US8496002B2 (en) 2007-06-12 2013-07-30 Civitas Therapeutics, Inc. Powder inhaler devices
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
CN103212078A (zh) * 2008-06-30 2013-07-24 诺瓦提斯公司 用于治疗帕金森病的包含mGluR调节剂的组合产品
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
AU2013334949B2 (en) * 2012-10-22 2018-08-09 Civitas Therapeutics, Inc. Levodopa formulations for rapid relief of Parkinson's disease
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Also Published As

Publication number Publication date
US20230053976A1 (en) 2023-02-23
EP3134077A1 (en) 2017-03-01
EP3134077A4 (en) 2017-12-20
AU2020239754A1 (en) 2021-01-14
CA2946165C (en) 2022-10-18
JP2017513866A (ja) 2017-06-01
AU2014391721B2 (en) 2020-07-16
KR20170008754A (ko) 2017-01-24
BR112016024502A8 (pt) 2021-06-29
IL248445A0 (en) 2016-12-29
EP3831375A1 (en) 2021-06-09
IL309959A (en) 2024-03-01
RU2016144340A3 (ja) 2018-05-22
US20170296498A1 (en) 2017-10-19
AU2014391721A1 (en) 2016-11-03
BR112016024502A2 (pt) 2017-08-15
WO2015163840A1 (en) 2015-10-29
KR20210144946A (ko) 2021-11-30
CA2946165A1 (en) 2015-10-29
RU2016144340A (ru) 2018-05-22
AU2020239754B2 (en) 2022-06-23
MX2016013741A (es) 2017-04-06
CN106659685B (zh) 2021-02-05
CN113209055A (zh) 2021-08-06
RU2698330C2 (ru) 2019-08-26
CN106659685A (zh) 2017-05-10
ZA201607833B (en) 2018-08-29

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
GB201418170D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418166D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418169D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
IL246999A0 (en) Methods for treating Alzheimer's disease
SG11201702819YA (en) Skin cosmetic
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
GB201418172D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
IL263188B (en) Treatment for Parkinson's disease
GB201417163D0 (en) Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
EP3177304A4 (en) Therapeutic nanoparticles for accumulation in the brain
EP3217973A4 (en) Melatonin in autoimmune disease
ZA201607833B (en) Rapid relief of motor fluctuations in parkinson's disease
GB2553527B (en) Headgear suitable for use in hydrotherapy
EP3109636A4 (en) Biomarker for parkinson's disease and use therefor
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
HK1220029A1 (zh) 在眼睛成像上和涉及眼睛成像的改進
GB201504144D0 (en) Treatment of Parkinson's disease
GB201414038D0 (en) Alzheimer's disease
GB201418079D0 (en) Eye care accessories
GB201410695D0 (en) Uses of oligouronates in cancer treatment